Patents Assigned to Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
  • Method for increasing cardiac inflow by administering a compound that binds RXFP1
    Patent number: 10799561
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 13, 2020
    Assignee: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
    Inventor: Thomas B. Dschietzig
  • Method for treating heart failure with preserved ejection fraction by administering human relaxin-2
    Patent number: 10226512
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: March 12, 2019
    Assignee: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
    Inventor: Thomas B. Dschietzig
  • METHOD AND COMPOSITION FOR TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Publication number: 20170182127
    Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
    Type: Application
    Filed: May 26, 2015
    Publication date: June 29, 2017
    Applicant: Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
    Inventor: Thomas D. Dschietzig